Page 14 - Athersys Inc News Today

The Cleveland-based regenerative medicine company didn't indicate how many shares it plans to sell. Athersys said it plans to use proceeds from the offering for working capital and general corporate purposes.

The Cleveland-based regenerative medicine company didn't indicate how many shares it plans to sell. Athersys said it plans to use proceeds from the offering for working capital and general corporate purposes.

/PRNewswire/ -- The Acute Ischemic Stroke Therapeutics Market share is expected to increase by USD 1524.49 million from 2022 to 2027, with an accelerated CAGR...

25.10.2022 - Brings deep industry experience spanning financial and operational roles to support Company and its new strategic directionJERSEY CITY, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering ... Seite 1

/PRNewswire/ -- The stem cell umbilical cord blood (UCB) market has been segmented by end-user (pharmaceutical, research institutes, hospitals, and biobanks)...

Global Stem Cell Umbilical Cord Blood (UCB) Market 2022-2026 The analyst has been monitoring the stem cell umbilical cord blood (UCB) market and it is...

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14th World Stroke Con...

/PRNewswire/ -- The "Global Stem Cells Market (2022-2027) by Product, Technology, Source, Applications, and Geography, with Competitive Analysis, Impact of...

U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping to a fresh low for the year. The Dow traded down 2.48% to 29,3...

Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Global Stem Cells Market (2022-2027) by Product, Technology, Source, Applications, and Geography, with...